OXURION overview

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – May 16, 2024 – 07:00 PM CET (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation 1 it has received a transparency notification as follows: Oxurion received a transparency notification on May 16, 2024, from Atlas Special Opportunities, LLC indicating that as of May 13, 2024, it held 1,000,850,000 shares...

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment 1 that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market opportunities of USD 3-6 billion. Leuven,...

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – May 13, 2024 – 07:00 PM CET (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation 1 it has received a transparency notification as follows: Oxurion received a transparency notification on May 9, 2024, from Atlas Special Opportunities, LLC indicating that as of May 2, 2024, it held 1,467,712,295 shares of...

` Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD Leuven, BELGIUM – May 6, 2024 – 6:00 PM CET , Oxurion NV (Euronext Brussels: OXUR), an innovative biopharmaceutical company based in Leuven, today announces important progress in its preclinical program targeting Geographic Atrophy (GA), a severe and underserved form of Age-Related Macular Degeneration (AMD). This recently launched program has reached the first step with the identification of 50 targets that...

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – April 25, 2024 – 07:00 PM CET (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation 1 it has received a transparency notification as follows: Oxurion received a transparency notification on April 25, 2024, from Atlas Special Opportunities, LLC indicating that as of April 19, 2024, it held 380,755,774...

Publication Annual Report – Annual Shareholders' Meeting Leuven, BELGIUM – April 15, 2024 – 05:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, has today published its annual report for the financial year 2023. The annual report for the year ending December 31, 2023 is available in the “Investors” section of the Company’s website, and can also be downloaded as a PDF. On this day as well, the Company has convened its Annual...

Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC Leuven, BELGIUM – April 11, 2024 – 07:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation 1 it has received two transparency notifications as follows: Oxurion received a first transparency notification on April 10, 2024, from Atlas Special Opportunities, LLC indicating that as of April 1, 2024, it...